Can RenSuper help Biocytogen reduce the bottlenecks in antibody development?
Biocytogen is turning antibody discovery into an AI-led industrial workflow. RenSuper could speed biologics R&D, but validation risk remains.
Can Passkey Therapeutics turn drug combinations into a faster clinical strategy?
AI drug platforms need clinical proof. Passkey’s new CMO must show whether Locksmith-picked combinations can move faster into patients.
Concept Life Sciences expands drug discovery model as OpenBench brings AI-enabled screening scale
Biotechs need faster hits with less upfront risk. Concept Life Sciences and OpenBench are testing whether success-based discovery can deliver.
AI can design proteins faster than labs can test them. LenioBio and Twist want to fix that bottleneck
AI can design proteins fast. Biology still sets the pace. LenioBio and Twist Bioscience are targeting drug discovery’s validation gap.
Insilico Medicine’s AI-designed anemia therapy begins Phase I testing in collaboration with TaiGen
Insilico Medicine and TaiGen advance AI-designed anemia drug ISM4808 into Phase I trials. Discover what this means for CKD therapy and AI drug discovery.
XtalPi and ReviR Therapeutics push AI-designed RTX-117 into human trials for rare neurological disorders
RTX-117 enters Phase 1 trials as an AI-designed therapy for Charcot-Marie-Tooth disease and VWM. Discover what this milestone means for rare disease drug discovery.
Ono Pharmaceutical strengthens early-stage pipeline with Congruence platform deal
Ono Pharmaceutical expands its Congruence alliance into neurology and immunology. Explore what this means for AI-driven drug discovery and pipeline risk.
Quiver Bioscience deal shows how Angelini Pharma is rethinking genetic epilepsy innovation
Angelini Pharma partners with Quiver Bioscience to discover new genetic epilepsy targets. Find out what this changes for drug discovery and patients.
Recursion Pharmaceuticals to spotlight self-driving lab model at NVIDIA GTC 2026
Recursion Pharmaceuticals spotlights its self-driving lab model at NVIDIA GTC 2026. Explore what this means for AI drug discovery and regulation.
Could Carterra Inc.’s Vega HT-SPR accelerate fragment and small-molecule discovery without compromising rigor
Find out how Carterra Inc.’s Vega HT-SPR platform could redefine primary screening and reshape early drug discovery workflows.